Lumosa Therapeutics Co Ltd (6535)

Currency in TWD
137.50
-7.50(-5.17%)
Closed·
6535 Scorecard
Full Analysis
Stock price often moves in the opposite direction of the market
6535 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
137.50145.00
52 wk Range
129.00400.00
Key Statistics
Bid/Ask
35.45 / 35.50
Prev. Close
204
Open
145
Day's Range
137.5-145
52 wk Range
129-400
Volume
347.63K
Average Volume (3m)
227.63K
1-Year Change
-31.28%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6535 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Lumosa Therapeutics Company Profile

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.

Compare 6535 to Peers and Sector

Metrics to compare
6535
Peers
Sector
Relationship
P/E Ratio
−59.2x−12.9x−0.5x
PEG Ratio
−3.300.090.00
Price/Book
13.5x1.9x2.6x
Price / LTM Sales
561.6x4.8x3.2x
Upside (Analyst Target)
58.6%0.0%44.6%
Fair Value Upside
Unlock0.8%6.5%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-0.63 / -0.41
Revenue / Forecast
8.90M / 5.00M
EPS Revisions
Last 90 days

6535 Income Statement

FAQ

What Is the Lumosa Therapeutics (6535) Stock Price Today?

The Lumosa Therapeutics stock price today is 137.50.

What Stock Exchange Does Lumosa Therapeutics Trade On?

Lumosa Therapeutics is listed and trades on the Taipei Exchange stock exchange.

What Is the Stock Symbol for Lumosa Therapeutics?

The stock symbol for Lumosa Therapeutics is "6535."

What Is the Lumosa Therapeutics Market Cap?

As of today, Lumosa Therapeutics market cap is 23.21B.

What Is Lumosa Therapeutics's Earnings Per Share (TTM)?

The Lumosa Therapeutics EPS (TTM) is -2.51.

When Is the Next Lumosa Therapeutics Earnings Date?

Lumosa Therapeutics will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is 6535 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lumosa Therapeutics Stock Split?

Lumosa Therapeutics has split 0 times.

How Many Employees Does Lumosa Therapeutics Have?

Lumosa Therapeutics has 43 employees.

What is the current trading status of Lumosa Therapeutics (6535)?

As of 19 Jul 2025, Lumosa Therapeutics (6535) is trading at a price of 137.50, with a previous close of 204.00. The stock has fluctuated within a day range of 137.50 to 145.00, while its 52-week range spans from 129.00 to 400.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.